Testosterone-related shortening of QTc interval in women with polycystic ovary syndrome.
BACKGROUND
The presence of several cardiovascular risk factors is observed in women with polycystic ovary syndrome (PCOS). On the other hand, the QTc interval duration, which is related to cardiac arrhythmia and sudden death, has not been investigated thoroughly in PCOS population.


OBJECTIVE
To investigate QTc interval duration and its relation to testosterone in women with PCOS.


METHODS
Cross sectional case-control study.


METHODS
Outpatient setting, tertiary university medical centre.


METHODS
We enrolled 119 consecutive patients in whom PCOS was diagnosed based on oligomenorrhea, infertility (>2 yr), ineffective ovarian stimulation, and ultrasonographic criteria. The control group (controls) included 64 age-matched healthy women without clinical or laboratory evidence of PCOS.


METHODS
In all participants we measured QTc interval duration on a standard electrocardiogram and determined plasma levels of high sensitivity C-reactive protein (hsCRP), endothelin-1 (ET-1), insulin, and testosterone.


METHODS
Shorter QTc interval duration in PCOS patients.


RESULTS
When compared to controls, PCOS patients displayed higher values of hsCRP (2.35+/-2.14 mg/l vs 1.18+/-1.24 mg/l; p=0.01), ET-1 (23.6+/-10.3 ng/l vs 12.9+/-20.7 ng/l; p=0.03), insulin (18.5+/-7.8 mIU/l vs 10.7+/-9.1 mIU/l; p=0.02), and testosterone (2.7+/-2.1 nmol/l vs 1.4+/-1.7 nmol/l; p=0.01). QTc interval in PCOS patients was significantly shorter than in controls (401+/-61 msec vs 467+/-61 msec; p=0.007), and inversely related to the plasma levels of testosterone (Spearman -0.45, p=0.005).


CONCLUSIONS
QTc interval in PCOS patients is short, and inversely associated with increased levels of testosterone. QTc interval duration is not part of an adverse cardiac risk profile in PCOS.
Vrtovec
B
B
Division of Cardiology, Ljubljana University Medical Centre, MC SI-1000, Ljubljana, Slovenia. bovrtovec@yahoo.com
Meden-Vrtovec
H
H
Jensterle
M
M
Radovancevic
B
B
D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D004562:Electrocardiography; D019332:Endothelin-1 / Q000097:blood; D005260:Female; D006329:Heart Conduction System / Q000502:physiology*; D006801:Humans; D007328:Insulin / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D012307:Risk Factors; D013739:Testosterone / Q000097:blood*
D019332:Endothelin-1; D007328:Insulin; D013739:Testosterone; D002097:C-Reactive Protein
J Clin Endocrinol Metab. 2005 May;90(5):2740-6
15741256
Jpn Heart J. 2002 Sep;43(5):487-93
12452306
Eur J Clin Invest. 2006 Oct;36(10):691-7
16968464
Circulation. 1991 Oct;84(4):1516-23
1914093
Circulation. 2005 Sep 20;112(12):1701-10
16157773
N Engl J Med. 2005 Mar 24;352(12):1223-36
15788499
JAMA. 1993 Dec 1;270(21):2590-7
8230644
Heart. 2002 Mar;87(3):193-4
11847147
Hum Reprod. 2004 Jan;19(1):41-7
14688154
Am J Cardiol. 2002 Nov 15;90(10):1050-5
12423702
Acta Physiol (Oxf). 2006 Nov-Dec;188(3-4):163-71
17054656